- S&P 500 Futures print three-day winning streak as bulls attack 3,900.
- US President Joe Biden’s covid relief package pass the Senate to return to Congress for details.
- US-Iran tussle intensified following American rejection to waive off Tehran’s sanctions.
- Oxford-AstraZeneca vaccine fails to tame South African variant of COVID-19.
S&P 500 Futures take the bids near 3,900 while refreshing an all-time high during early Monday. The risk barometer seems to cheer increasing odds of $1.9 trillion coronavirus (COVID-19) stimulus from the US. In doing so, the American equity futures ignore recent tension between Washington and Tehran as well as downbeat news concerning the vaccine during a light calendar day in Asia.
With the Vice President’s vote pushing US President Joe Biden’s optimistic plan through the Senate, the much-awaited relief package is on the way to hit the floor. However, Congress is not only divided on the final amount but also the details and hence the discussion may take longer before Biden gets to sign the bill.
Elsewhere, US President Biden’s rejection to not take back the Trump administration’s sanctions on Iran pushed the Tehran government to ask for America’s return to the 2015 accord, as well as the reversal of all punitive measures, to not move ahead with their arms embargo.
It should be noted that the covid vaccine front has another negative news, in addition to the previous delay in deliveries and production, suggesting that the Oxford-AstraZeneca vaccine falls short of taming the covid variant from South Africa.
Amid these plays, stocks in Asia-Pacific stay bid while the US 10-year Treasury yields remain strong around the highest level marked since March 2020 on Friday.
Moving on, a light calendar and off in New Zealand keeps the market players directed towards stimulus and vaccine headlines for fresh direction.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.